Agreement Integrates Accellix’s Proprietary Quality Control Optic System, Cartridges, Reagents and Software into Orgenesis’ Point of Care Cellular Therapy Platform

Orgenesis Inc. a leading cell and gene therapy enabling company provides centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., and localized point-of-care processing and development services. Orgenesis Inc. announced a co-development agreement with Accellix, Inc, which enable Orgenesis to integrate Accellix’s proprietary optic system, cartridges, reagents and software into Orgenesis’ Point of Care (“POCare”) cellular therapy processing services and platform.  The integration is designed to further advance Orgenesis’ quality control systems.

Orgenesis’ POCare cell therapy platform has been specifically designed to collect, process and supply cells within the patient care location for various therapeutic treatments.  The goal of the platform is to reduce the cost and complexity of supplying cell and gene therapies by integrating automated closed systems, processing technologies and unique technologies enabling cell selection, cell processing, cell transfection and quality control sensors.  The Accellix assay delivery platform advances the quality control aspects of Orgenesis’ POCare platform by providing actionable multi-parameter results for analyzing and processing live cells.

Vered Caplan, CEO of Orgenesis, stated, “By partnering with Accellix and integrating its advanced optic technologies, cartridges and software, we believe that this will advance Orgenesis’ processing capabilities for different types of cells for our POCare services and platform.  We believe the Orgenesis POCare platform can deliver a transformative option to the cell and gene therapy market that will lower costs in order to potentially bring our autologous therapies to patients in a cost effective, high quality and scalable manner.”

During the summer, Accellix underwent several changes. It had several major additions to its senior leadership team with the appointment of Nir Nimrodi as Executive Chairman and Rey Mali as Vice President Sales and Marketing. The company also changed its name from LeukoDx, Inc.  to  Accellix, Inc.

Mr. Nimrodi commented, “The change of our name to Accellix completes our re-focusing evolution. We want to make it clear to our customers that we are committed to enabling their critical QC requirements. Aligned with our customers, we understand that each patient batch they process is precious. Applying our multi-parametric cell analysis system, as part of the process of releasing cells to treat a patient, will be the culmination of everything we aim to achieve and why we exist. We look forward to continued progress in developing our system and to commercializing it with cell and gene therapy companies globally.”

Mrs. Mali commented: “The cell therapy market needs a new testing paradigm that can deliver rapid results when needed, and one that can scale to meet the expanding adoption of therapy regimens. The Accellix platform is designed for this need and is validated by market leading companies.”

About Accellix

Accellix Inc. provides assay migration and delivery platform for on demand process analytics.  The Accellix system is an assay delivery platform that provides quick, reliable, flow cytometry with multi-parameter results using a small instrument and room temperature stable cartridge.  The Accellix platform offers simplicity of use, flexibility and automated data analysis.

About Orgenesis

Orgenesis is a biotechnology company specializing in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry.  Orgenesis operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global.  Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients.  The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting.  Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies.  Additional information is available at:

Source: Globes news wire